Sun Pharmaceutical Industries Limited has announced that all resolutions proposed at its 34th Annual General Meeting (AGM) were passed by shareholders with the requisite majority. The meeting, held on July 31, 2026, concluded successfully, with the independent Scrutinizer submitting his final report to the company confirming the outcome. This approval validates the corporate actions and strategic decisions outlined in the notice of the AGM dated July 06, 2026.

The resolutions are now effective in accordance with the applicable provisions of law. The company has submitted the official voting results to the relevant exchanges and stakeholders. The detailed Scrutinizer Report is accessible to investors and shareholders on the company’s website at www.sunpharma.com . This process ensures transparency and compliance with regulatory requirements governing general meetings.

Key Details of the 34th AGM

The following table summarizes the key procedural details of the recent annual general meeting:

Regulatory Compliance and Reporting

Anoop Deshpande, Company Secretary and Compliance Officer of Sun Pharmaceutical Industries Limited, certified the results. The submission confirms that the voting process adhered to statutory guidelines. Shareholders are advised to refer to the company’s website for the complete Scrutinizer Report and voting breakdown. No further action is required from shareholders regarding these specific resolutions.

Sun Pharmaceutical Industries Limited has received regulatory approval from the Brazilian Health Regulatory Agency, ANVISA, to manufacture and market semaglutide injection in Brazil. The approval permits the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise, marking a significant expansion of its diabetes portfolio in Latin America. Management intends to launch the product in the next few days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil, capitalizing on a semaglutide injectable market estimated at approximately USD 413 million (IQVIA, MAT June 2026).

The intimation was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, on July 29, 2026. The filing confirms that Sun Pharma holds the necessary manufacturing and marketing rights for the drug in the region. The product will be available as a pre-filled, multi-dose injectable pen, offering flexible once-weekly dosing options for patients.

Product Specifications

The approved semaglutide formulation is designed for ease of use and adherence, featuring two distinct strengths:

Management Commentary

Aalok Shanghvi, Chief Operating Officer at Sun Pharma, stated that the approval expands access to an evidence-based treatment option for people living with inadequately controlled type 2 diabetes. He noted that the milestone reflects the strength of the company's development and manufacturing capabilities and its commitment to delivering high-quality medicines across global markets.

Digvijay Singh, Regional Head for Brazil & LATAM, emphasized that this approval marks an important step in strengthening the diabetes portfolio in Brazil. He expressed anticipation for working closely with the partner to make this treatment option available to patients and support better diabetes care across the country.

Market Context

The entry into the Brazilian semaglutide market positions Sun Pharma to compete in a sector valued at approximately USD 413 million, according to IQVIA data for the month ending June 2026. By securing both manufacturing and marketing approvals, Sun Pharma bypasses the need for third-party sourcing, potentially improving margin structures compared to pure distribution deals. The partnership with Hypera Pharma leverages local expertise to accelerate market penetration, while the dual-strength offering (2 mg and 4 mg) allows for dose titration, a critical factor in patient adherence for chronic conditions like type 2 diabetes. This move aligns with Sun Pharma's broader strategy to expand its presence in Global Emerging Markets, where it already maintains a significant footprint alongside its US generics business.